Immunovia, Inc. is the exclusive provider of the IMMray® PanCan-d test, a blood test for the early detection of pancreatic adenocarcinoma (PDAC).
The IMMray PanCan-d test relies on the IMMray microarray technology, where single chain fragment antibodies are produced and then printed onto a slide in a measured amount as a microarray of different antibody biomarkers. 14 microarrays are printed on each slide.
When a patient’s serum sample is received at Immunovia, Inc., the patient’s serum is biotinylated and then applied to the microarray; the microarray is scannedusing a fluorescence scanner to measure antibody responses to patient serum; and then antibody response levels are entered into an algorithm to determine a result of “High-Risk Signature Present”, “Negative for High-Risk Signature” or Borderline result.
JOIN THE LIVE EVENT
26 Forest Street, Suite 110 Marlborough, MA 01752
Return to the MAGIC 2021 Conference Streaming
Search tags: Pancreatic Cancer, Laboratory Test, Biomarkers, Blood Test